Investor Update Lunch at the American Epilepsy Society 2018 Annual Meeting, hosted by Zogenix

Monday, December 3 – 12-2pm CST

The event will feature presentations by two Key Opinion Leaders (KOLs) on the recent results from the Phase 3 program for Fintepla® (fenfluramine HCI) in Dravet syndrome. Both KOLs will be available to answer questions at the conclusion of the event.

Zogenix’s management team will provide a summary of the information from other Company-sponsored posters to be presented at AES, as well as a general corporate update.